Ascendis Pharma A/S
ASND
152 hedge funds and large institutions have $8.27B invested in Ascendis Pharma A/S in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 79 increasing their positions, 40 reducing their positions, and 20 closing their positions.
254% more call options, than puts
Call options by funds: $37.5M | Put options by funds: $10.6M
98% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 40
16% more capital invested
Capital invested by funds: $7.13B → $8.27B (+$1.14B)
0.89% more ownership
Funds ownership: 100.54% → 101.43% (+0.89%)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
1% less funds holding
Funds holding: 154 → 152 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$228M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$211M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$143M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$95.7M |
| 5 |
Janus Henderson Group
London,
|
+$77.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$119M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$51.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$41.2M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$27.6M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.6M |
ASND Hedge Fund Activity: Q3 2020 in Review
152 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2020, worth a combined $8.27B — up 16% from $7.13B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ASND and 19 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 79 added.
The largest buyer was Artisan Partners, adding an estimated $228M. The largest seller was OrbiMed, cutting an estimated $119M.
- 152 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2020, down from 154 in Q2 2020.
- Funds reported $8.27B of Ascendis Pharma A/S stock for Q3 2020, up 16% quarter-over-quarter.
- 19 funds opened new Ascendis Pharma A/S positions in Q3 2020 and 20 closed out, a net change of -1 holder.
- The largest Ascendis Pharma A/S buyer in Q3 2020 was Artisan Partners, an estimated $228M added.
- The largest Ascendis Pharma A/S seller in Q3 2020 was OrbiMed, an estimated $119M sold.
Based on aggregated 13F filings for Q3 2020.